14 completed, 3 recruiting, 3 unknown, 2 not yet recruiting. 23 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 14, Recruiting 3, Unknown 3, Not yet recruiting 2, Terminated 1 |
| Phase 2 | 6 | Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1 |
Follow Bordetella Infections: new trials by email Literature Review of Bordetella Infections trials Research Report on Bordetella Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Tdap vaccine - Pertussis (Whooping Cough), Diphtheria | Phase 1 | Not yet recruiting | Changchun BCHT Biotechnology Co. | 96 | 2026-04-20 | 2026-03-25 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis Biological: Bordetella pertussis J820 - Pertussis (Whooping Cough) | Phase 1 | Recruiting | Dalhousie University | 60 | 2025-11-24 | 2025-12-04 |
| Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine DTacP (one-dose booster), DTacP (three-dose primary vaccination), DT (one-dose booster) - Diphtheria, Tetanus | Phase 1 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 460 | 2023-12-23 | 2024-01-03 |
| A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp), 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）, Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT) - Diphtheria, Tetanus | Phase 1 | Completed | CanSino Biologics Inc. | 180 | 2023-12-06 | 2026-08-07 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Establishing a Controlled Human Infection Model of Bordetella Pertussis Bordetella pertussis D420 - Pertussis | Phase 1 | Completed | Dalhousie University | 79 | 2022-01-28 | 2026-09-03 |
| Pertussis Acellular Vaccine Adjuvanted With TQL1055 TQL1055, Acellular pertussis vaccine - Pertussis | Phase 1 | Terminated | Adjuvance Technologies, Inc. | 72 | 2021-04-06 | 2022-11-01 |
| Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed, Diphtheria and Tetanus Combined Vaccine, Adsorbed, Diphtheria-tetanus-acellular pertussis vaccine - Diphtheria, Tetanus | Phase 1 | Completed | CanSino Biologics Inc. | 400 | 2020-04-28 | 2022-10-31 |
| A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Vaccine GamLPV, Placebo - Whooping Cough | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 50 | 2019-06-04 | 2019-07-31 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV - Diphtheria, Tetanus | Phase 1 | Completed | LG Chem | 42 | 2017-07-03 | 2019-08-29 |
| A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Vaccine GamLPV, Placebo - Whooping Cough | Phase 1 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 36 | 2017-06-13 | 2017-12-28 |
| Viaskin Pertussis Vaccine Trial Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo - Whooping Cough | Phase 1 | Completed | DBV Technologies | 102 | 2016-09-05 | 2020-03-02 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 - Tetanus, Diphtheria | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1363 | 2015-10-22 | 2022-03-23 |
| Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine BPZE1, Placebo - Pertussis, Whooping Cough | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 54 | 2015-09-01 | 2026-02-27 |
| Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) aP booster, TdaP booster, Licensed TdaP booster (Boostrix®) - Pertussis | Phase 1 | Completed | Novartis | 315 | 2015-04-01 | 2016-03-24 |
| Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap - Diphtheria, Tetanus | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 40 | 2013-08-01 | 2016-03-07 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis - Pertussis, Tetanus | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 43 | 2012-09-01 | 2014-02-21 |
Showing 20 of 23. Sign in to see all of them.
Whooping Cough (23) · Diphtheria (14) · Tetanus (14) · Poliomyelitis (3) · Haemophilus Infections (2) · Hepatitis B (2) · Infections (2) · Respiratory Tract Infections (1) · Trismus (1)
Bacterial Infections (23) · Bacterial Infections and Mycoses (23) · Gram-Negative Bacterial Infections (23) · Respiratory Tract Diseases (23) · Respiratory Tract Infections (22) · Infections (21) · Actinomycetales Infections (14) · Clostridium Infections (14) · Corynebacterium Infections (14) · Gram-Positive Bacterial Infections (14) · Nervous System Diseases (4) · Central Nervous System Diseases (3) · Central Nervous System Infections (3) · Enterovirus Infections (3)
Tetanus Toxoid (8) · Boostrix (3) · Diphtheria-Tetanus-acellular Pertussis Vaccines (2) · Vaccines, Combined (2) · adacel (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Aging (1) · Immunization, Secondary (1) · Pentavac (1) · Poliovirus Vaccine, Inactivated (1) · Saline Solution (1)
Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Sanofi Pasteur, a Sanofi Company (3) · CanSino Biologics Inc. (2) · Dalhousie University (2) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · LG Chem (2) · Adjuvance Technologies, Inc. (1) · Changchun BCHT Biotechnology Co. (1) · DBV Technologies (1) · Green Cross Corporation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1) · Novartis Vaccines (1)
China (6) · Belgium (2) · Canada (2) · Russia (2) · South Korea (2) · Sweden (2) · United States (2) · Australia (1) · Japan (1) · Switzerland (1)
Marina Rusanova (2) · Nabil Al-Tawil, MD, PhD (2) · Camille Locht, PhD (1) · Claire Anne Siegrist, M.D (1) · Geert Leroux-Roels, Prof. Dr. (1) · Jiawei Xu (1) · Nam Joong Kim (1) · Rigmor Thorstensson, PhD (1) · Scott A. Halperin, MD (1) · Sean R Bennett, MD PhD (1) · WJ Kim (1) · Wang Yanxia (1) · Wenge Tang (1)
PMID 29172945, PMID 24261996, PMID 24421886, PMID 24793938, PMID 24794369, PMID 31945015, PMID 32687804, PMID 32896653, PMID 40977696, PMID 42369467
2014 (1), 2015 (1), R34AI148056 (1)